<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744949</url>
  </required_header>
  <id_info>
    <org_study_id>2018-1410</org_study_id>
    <nct_id>NCT03744949</nct_id>
  </id_info>
  <brief_title>ED50 and ED95 of Remifentanil for Intubation Without NOL Variation</brief_title>
  <acronym>RemiTrach</acronym>
  <official_title>Determination of the ED50 and ED95 of Remifentanil to Perform Tracheal Intubation Without Significant NOL Index Variation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciusss de L'Est de l'Île de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ciusss de L'Est de l'Île de Montréal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our aim, in this study, is to elucidate the optimal dosing range (ED50 and ED95) of bolus
      remifentanil in order to counter the painful stimuli resulting from direct laryngoscopy and
      tracheal intubation by using the NOL index. In order to maximize the clinical relevance of
      our findings, induction of general anesthesia will be done with standard medications and
      doses and laryngoscopy will be done with the Macintosh laryngoscope, the most common tool
      used for intubation in the operating room
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: There are no study so far that determined the ED50 and ED95 of remifentanil to
      perform tracheal intubation by using the NOL index as the criterion measured to determine the
      failure (painful intubation) or the success (pain free intubation) of the assessed procedure.

      Objectives: To determine the ED50 and ED95 of remifentanil bolus to perform tracheal
      intubation without NOL index variating over threshold for nociceptive response (determined as
      a NOL index going over 20 - peak value of maximum 20) using the Macintosh blade when
      obtaining good conditions of intubation in anesthetized patients. Good conditions of
      intubation will be determined as obtaining a Cormack-Lehane grade I and II.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Four groups of patients. Randomization into the dose of remifentanil given according to a randomization list for a total number of patients of 80.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>remifentanil will be given by a dosage of 0.5-1.0-1.5-2.0 µg/kg of adjusted body weight bolus according to randomization, by an infusion pump over 30 seconds</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>determine ED95 of remifentanil bolus in mcg/kg for tracheal intubation</measure>
    <time_frame>in the surgery</time_frame>
    <description>The primary goal of this study is to determine the ED95 of remifentanil bolus to perform tracheal intubation without NOL index varying over 20 (peak maximal value of 20) using the Macintosh blade when obtaining a Cormack-Lehane grade I or II of intubation in anesthetized patients (the size of the blade will be chosen according to patient characteristics described in the user's manual for each blade and published in previous literature). This primary outcome will be expressed in mcg/kg of remifentanil.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NOL maximal value after intubation (NOL is an index without unit going from 0 to 100)</measure>
    <time_frame>in the surgery</time_frame>
    <description>After tracheal intubation NOL index maximal value will be evaluated and compared between the 4 doses of remifentanil in mcg/kg received in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of NOL index after tracheal intubation; DELTA NOL (no unit)</measure>
    <time_frame>in the surgery</time_frame>
    <description>After tracheal intubation DELTA NOL index will be evaluated and compared between the 4 doses of remifentanil in mcg/kg received in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in seconds NOL spends above 25 after tracheal intubation (in seconds)</measure>
    <time_frame>in the surgery</time_frame>
    <description>Time in seconds spent above 25 of NOL index and comparison between the 4 doses of remifentanil used in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve for NOL index after tracheal intubation (no unit)</measure>
    <time_frame>in the surgery</time_frame>
    <description>Compare the AUC of NOL after tracheal intubation between the 4 doses of remifentanil used in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Maximal value after tracheal intubation (in beat per minutes)</measure>
    <time_frame>in the surgery</time_frame>
    <description>To compare maximal heart rate values reached after tracheal intubation between the 4 doses of remifentanil used in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate variation (DELTA Heart Rate) after tracheal intubation (in beats per minute)</measure>
    <time_frame>in the surgery</time_frame>
    <description>To compare the DELTA Heart Rate after tracheal intubation between the 4 doses of remifentanil used in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in seconds that Heart Rate spends above threshold of 10%; in seconds</measure>
    <time_frame>in the surgery</time_frame>
    <description>To compare the time in seconds between the 4 doses of remifentanil that Heart Rate spends above teh threshold of 10% of variation above normal prestimulus values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of Heart Rate after tracheal intubation (no unit)</measure>
    <time_frame>in the surgery</time_frame>
    <description>To compare AUC of Heart Rate values after tracheal intubation between teh 4 different doses of remifentanil used in this study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Intubation; Difficult or Failed</condition>
  <arm_group>
    <arm_group_label>Remifentanil dose 0.5 ug/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentnil dose 1 ug/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil will be given (dosage of 1.0 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil dose 1.5 ug/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil dose 2 ug/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil dose 0.5 ug/kg</intervention_name>
    <description>Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds</description>
    <arm_group_label>Remifentanil dose 0.5 ug/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil dose 1 ug/kg</intervention_name>
    <description>Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds</description>
    <arm_group_label>Remifentnil dose 1 ug/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil dose 1.5 ug/kg</intervention_name>
    <description>Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds</description>
    <arm_group_label>Remifentanil dose 1.5 ug/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil dose 2 ug/kg</intervention_name>
    <description>Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds</description>
    <arm_group_label>Remifentanil dose 2 ug/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA status I or II

          -  Mallampati class I or II

          -  Patients &gt; 18 years old and &lt;65 years (defining elderly patients)

          -  Elective general, gynecological, orthopedic, plastic or urological surgery under
             general anesthesia

          -  Type of surgery that usually necessitate endotracheal intubation and controlled
             ventilation

        Exclusion Criteria:

          -  Patient refusal

          -  History of psychiatric diseases or psychological problems (including mental
             retardation); inability to give consent; language barrier.

          -  Anticipated difficult airway (Mallampati class III and IV, thyromental distance &lt; 6
             cm, mouth opening &lt; 3 cm, neck extension &lt;80° and neck flexion &lt;35°, inability to
             prognath, meaning bringing lower mandibular before the upper maxilla)

          -  Patient with history of neck rigidity or instability

          -  BMI &gt; 30 kg/m2

          -  Anticipated difficult ventilation (patients with beard, obesity with BMI more than 30
             kg/m2)

          -  Patient with history of oropharyngeal or tracheal surgery (excluding adenoidectomy,
             tonsillectomy and teeth removal)

          -  Severe coronary artery disease

          -  Serious cardiac arrhythmias (including atrial fibrillation)

          -  Use of β-blockers (all types)

          -  History of opioid or illicit drug substance abuse

          -  Chronic use of psychotropic and/or opioid drugs

          -  Allergy to remifentanil or propofol

          -  Pregnancy

          -  Contraindications to mask ventilation (gastrointestinal tract obstruction, pregnancy,
             active not-treated gastroesophageal reflux disease, non-fasting patients)

          -  Unexpected difficult airway requesting excessive, possibly painful airway
             manipulations

          -  Requiring hemodynamic support with vasopressors or inotropes 2 min before laryngoscopy
             to 5 min after insertion of endotracheal tube
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Richebe, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSS de l'Est de Montreal, Hopital Maisonneuve Rosemont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadia Godin</last_name>
    <phone>514-252-3400</phone>
    <phone_ext>4620</phone_ext>
    <email>ngodin.hmr@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Richebe, MD PhD</last_name>
    <phone>514-252-3400</phone>
    <phone_ext>4620</phone_ext>
    <email>philipperichebe@live.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Maisonneuve Rosemont</name>
      <address>
        <city>Montréal-Est</city>
        <state>Quebec</state>
        <zip>H1T2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Godin</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>3193</phone_ext>
      <email>ngodin.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Philippe Richebe, MD PhD</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>4620</phone_ext>
      <email>philipperichebe@live.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 11, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ciusss de L'Est de l'Île de Montréal</investigator_affiliation>
    <investigator_full_name>Philippe Richebe</investigator_full_name>
    <investigator_title>Director of Research in the Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Tracheal intubation</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>Pain</keyword>
  <keyword>NOL index</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

